NEU Grand Library | TRNC Library


	NEU GRAND LIBRARY Opening Hours: Monday-Saturday, 08:00-20:00 \| E-mail: library@neu.edu.tr

You are not logged in

Show Basket

Home

Advanced Search

Back

Add to Basket

Brief display

MARC Display

Reserve

A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (actair). (Bahceciler, Nerin N.)

Bibliographical information (record 266455)

A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (actair).
Author:	Bahceciler, Nerin N. Search Author in Amazon Books
Publisher:	Expert Reviews,

Edition:	2014.
Classification:	QW504
URL:	http://library.neu.edu.tr:2048/login?url=http://dx.doi.org/10.1586/14760584.2014.972949

Detailed notes

- Subcutaneous allergen-specific immunotherapy has long been used in the treatment of allergic rhinitis and/or asthma and its efficacy has been confirmed. However, due to the discomfort of injections and the risk of severe adverse reactions, alternative routes of allergen administration have emerged. Delivery of allergens through the mucosal route had been proposed and investigated thoroughly, confirming the sublingual route to be the most efficacious. Later, the efficacy and safety of this route have been documented by numerous controlled trials both for house dust mite (HDM) and pollens. Recently, sublingual orodispersable grass pollen allergen tablets were in use followed by the newly developed HDM allergen tablets with satisfactory clinical results: Moreover, very recently 1 year of HDM tablet treatment was demonstrated to exert its clinical efficacy 1 year after discontinuation of tablet IT. The persistence of efficacy after only 1 year of treatment is a new and promising era. Currently, Sublingual Immunotherapy is the most easily administered and safe treatment option until more immunogenic, less allergenic and more efficient allergen extracts are developed.